Research progress of chimeric antigen receptor -T cells in the treatment of multiple myeloma

doi:10.11958/20180816

Tianjin Medical Journal ›› 2018, Vol. 46 ›› Issue (10): 1127-1131.doi: 10.11958/20180816

Previous Articles Next Articles

Research progress of chimeric antigen receptor -T cells in the treatment of multiple myeloma

DONG Qian-qian1＊, WU Wei-wei1＊, ZHANG Xi-you1, CHEN Feng1, 2△, LI Dan-dan1

1 Department of Hematology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China; 2 Department of Neuro-Oncology, Beijing Tiantan Hospital, Capital Medical University △Corresponding Author E-mail: chenfeng406@sina.com

Received:2018-05-23 Revised:2018-08-15 Published:2018-10-15 Online:2018-11-09

DONG Qian-qian, WU Wei-wei, ZHANG Xi-you, CHEN Feng, LI Dan-dan. Research progress of chimeric antigen receptor -T cells in the treatment of multiple myeloma[J]. Tianjin Medical Journal, 2018, 46(10): 1127-1131.

Abstract

Abstract: Abstract: Chimeric antigen receptor T cell (Car-T) is a kind of new targeted therapy. With the continuous progress of basic and clinical research, more and more target antigens have been found, making the possible indications for Car-T gradually expanded. Multiple myeloma (MM) is still considered an incurable disease, Car-T immunotherapy based on genetic engineering and targeted therapy is becoming a new approach for treating relapsed and refractory MM. This article briefly reviews the recent progress of this field

Key words: multiple myeloma, receptors, antigen, T-cell, immunotherapy, review

[1]	SU Ya, ZHANG Dongwei, YU Minghui, WANG Chunhua, WU Yueyue. Observation on the clinical efficacy of compound kushen injection combined with targeted and immune therapy in the treatment of advanced hepatocellular carcinoma [J]. Tianjin Medical Journal, 2026, 54(3): 324-328.
[2]	ZHAO Lanjun, LI Lianghui, MA Xin, GONG Jiaojiao, ZHENG Chenhui, SHI Lin. The effect of andrographolide regulating STAT3/GPX4 pathway on proliferation and apoptosis of myeloma cells [J]. Tianjin Medical Journal, 2026, 54(1): 8-13.
[3]	XIANG Lili, WANG Qian, MENG Yanna, FU Jie, ZHANG Pu. Efficacy of lenalidomide combined with bortezomib and dexamethasone in the treatment of multiple myeloma [J]. Tianjin Medical Journal, 2025, 53(6): 665-669.
[4]	JU Feng, ZHAO Guangyu, LIU Yin, JIANG Xin, YIN Dengyang, GU Hong. The prognostic value of serum IFN-γ, MBL and sFas expression levels in patients with multiple myeloma [J]. Tianjin Medical Journal, 2025, 53(2): 141-145.
[5]	CHEN Minchun, XUE Runqing, ZHAO Xin, ZHANG Meng, YE Dan, ZHANG Jingyi, ZHENG Jie. Development and evaluation of the tumor vaccine TCL/CpG@GNP [J]. Tianjin Medical Journal, 2025, 53(10): 1021-1026.
[6]	XU Tong, ZHANG Wei, LIU Yonghui. Research progress of dendritic cell exosomes as vaccine carriers [J]. Tianjin Medical Journal, 2025, 53(10): 1115-1120.
[7]	FANG Jie, HUANG Rui, ZHENG Honghui, JIA Qianqian, BAO Jing. miR-9-5p-induced autophagy and apoptosis in multiple myeloma cells by targeting TIMP2 [J]. Tianjin Medical Journal, 2024, 52(8): 785-790.
[8]	LIU Zhichao, LI Xiaohe, ZHOU Honggang, ZHANG Na. Overview of animal models of idiopathic inflammatory myopathy-associated interstitial lung disease [J]. Tianjin Medical Journal, 2024, 52(7): 709-713.
[9]	WANG Ningfang, ZHAO Chongshan, LIU Fang, ZHAO Penghao, ZHANG Dongdong, CAI Zhuowen, CAI Fangfang. The detection and clinical significance of microparticles derived from lymphocytes in patients with multiple myeloma [J]. Tianjin Medical Journal, 2024, 52(4): 409-415.
[10]	LIU Huimin, XU Xuanxuan, WANG Yuanli, XIONG Tao, TANG Yuanyan. Impacts of CircBACH1 on proliferation, apoptosis and chemosensitivity of multiple myeloma cells by regulating miR-140-5p /MDM2 axis [J]. Tianjin Medical Journal, 2023, 51(11): 1170-1175.
[11]	WANG Yingying. Analysis of the effect of sublingual immunotherapy for allergic rhinitis in children and judgment of obvious effect time [J]. Tianjin Medical Journal, 2023, 51(11): 1255-1257.
[12]	XU Jiawei, GUO Yihui, SONG Hui, CHENG Weimin. The research progress on the mechanism of Wnt/β-catenin signaling pathway involved in multiple myeloma [J]. Tianjin Medical Journal, 2022, 50(8): 888-891.
[13]	XIE Yunfan, LIU Mi, TIAN Yi. Research progress on effects of sevoflurane on apoptosis related signal pathways of hippocampal neurons [J]. Tianjin Medical Journal, 2022, 50(8): 892-896.
[14]	LI Xiyuan, ZHU Zhixin, ZHAO Hailong . Recent advances in the mechanisms of drug resistance and treatment of BRAF-mutant melanoma [J]. Tianjin Medical Journal, 2022, 50(2): 214-219.
[15]	LEI Xiaomei, QU Jiaquan, TAN Tan . Progress in clinical trials of PD-1 inhibitor monoclonal antibody for nasopharyngeal carcinoma [J]. Tianjin Medical Journal, 2022, 50(2): 220-224.

Research progress of chimeric antigen receptor -T cells in the treatment of multiple myeloma

Cite this article

PDF (PC)

Knowledge

Abstract

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments